Vault-13

SR One Capital Management, LP

Redwood City, CA · CIK 1910264 · 13F filing filed 2026-05-14

SEC-registered investment adviser since 2020 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Redwood City, CA (main office)United States United Statesabout 10
LondonUnited Kingdom United Kingdom5

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$915.4m reported value +29.6% vs Q4 2025
14positions
96.5%in top 10
1 new 0 added 0 reduced 0 sold out vs Q4 2025

Holdings, Q1 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ARCELLX INC COMMON STOCK ACLX ACLX 2,346,630 $269.4m29.43% 29.43% UnchangedShares held: Q2 2025 2.3m, Q3 2025 2.3m, Q4 2025 2.3m, Q1 2026 2.3m
2 VERADERMICS INC COMMON STOCK MANE MANE 2,401,868 $151.7m16.57% 16.57% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 2.4m
3 ZENAS BIOPHARMA INC COM ZBIO ZBIO 5,037,854 $98.5m10.76% 10.76% UnchangedShares held: Q2 2025 4.9m, Q3 2025 4.9m, Q4 2025 5.0m, Q1 2026 5.0m
4 CRISPR THERAPEUTICS AG NAMEN AKT CRSP CRSP 2,038,763 $97.0m10.59% 10.59% UnchangedShares held: Q2 2025 1.0m, Q3 2025 2.0m, Q4 2025 2.0m, Q1 2026 2.0m
5 DESIGN THERAPEUTICS INC COM DSGN DSGN 6,526,476 $69.4m7.59% 7.59% UnchangedShares held: Q2 2025 6.5m, Q3 2025 6.5m, Q4 2025 6.5m, Q1 2026 6.5m
6 ORIC PHARMACEUTICALS INC COM ORIC ORIC 4,514,929 $58.5m6.39% 6.39% UnchangedShares held: Q2 2025 4.5m, Q3 2025 4.5m, Q4 2025 4.5m, Q1 2026 4.5m
7 ALUMIS INC COM ALMS ALMS 1,959,896 $43.2m4.72% 4.72% UnchangedShares held: Q2 2025 2.0m, Q3 2025 2.0m, Q4 2025 2.0m, Q1 2026 2.0m
8 MINERALYS THERAPEUTICS INC COM MLYS MLYS 1,563,966 $42.4m4.63% 4.63% UnchangedShares held: Q2 2025 3.1m, Q3 2025 2.1m, Q4 2025 1.6m, Q1 2026 1.6m
9 ARS PHARMACEUTICALS INC COM SPRY SPRY 4,012,903 $32.2m3.52% 3.52% UnchangedShares held: Q2 2025 4.0m, Q3 2025 4.0m, Q4 2025 4.0m, Q1 2026 4.0m
10 ORUKA THERAPEUTICS INC COM ORKA ORKA 430,330 $21.1m2.31% 2.31% UnchangedShares held: Q2 2025 430.3k, Q3 2025 430.3k, Q4 2025 430.3k, Q1 2026 430.3k
11 OCULIS HOLDING AG ORDINARY SHARES OCS OCS 641,022 $17.0m1.86% 1.86% UnchangedShares held: Q2 2025 322.5k, Q3 2025 322.5k, Q4 2025 641.0k, Q1 2026 641.0k
12 NKARTA INC COM NKTX NKTX 3,333,333 $7.0m0.77% 0.77% UnchangedShares held: Q2 2025 3.3m, Q3 2025 3.3m, Q4 2025 3.3m, Q1 2026 3.3m
13 ENGENE HOLDINGS INC COM COM 747,750 $5.1m0.56% 0.56% UnchangedShares held: Q2 2025 747.8k, Q3 2025 747.8k, Q4 2025 747.8k, Q1 2026 747.8k
14 ULTRAGENYX PHARMACEUTICAL IN COM RARE RARE 137,753 $2.9m0.32% 0.32% UnchangedShares held: Q2 2025 0, Q3 2025 0, Q4 2025 137.8k, Q1 2026 137.8k